Base de dados : MEDLINE
Pesquisa : D02.092.471.683.530 [Categoria DeCS]
Referências encontradas : 139 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 14 ir para página                         

  1 / 139 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:25510052
[Au] Autor:Lazarov N; Lazarov L; Lazarov S
[Ti] Título:[Effective tocolysis without ß-agonists].
[So] Source:Akush Ginekol (Sofiia);53 Suppl 2:38-41, 2014.
[Is] ISSN:0324-0959
[Cp] País de publicação:Bulgaria
[La] Idioma:bul
[Ab] Resumo:UNLABELLED: Many years the ß-mimetics (Partussisten, Gynipral) were first line tocolytic agents in terms of delaying premature delivery in our country. As these medicaments have been withdrawn from the pharmacy network, some concerns began to appear among our colleges considering the administration of other tocolytics and their effectiveness. Our goal is to compare the efficacy of other tocolytics with ß-mimetics. That is why we reviewed the structure of premature deliveries in the University Hospital "Stoyan Kirkovich", Stara Zagora for two periods: 01.01.2013 - 31.12. 2013 and 01.01.2014 - 01.06.2014. RESULTS: 45 of 326 pregnancies (13.8%) > 20 weeks of gestation for 2013, treated with Gynipral have ended with a premature delivery vs. 13 of 110 pregnancies (11.8%), treated with magnesium (Mg SO4, Magnerich, Magnerot), calcium channel blockers and spasmolyticsfor the period - 01:01.2014 - 01.06.2014. CONCLUSION: The results show, that at this stage, several months after the cessation of use of ß-mimetics, there is no rise of number and percentage of premature deliveries, but there is even a tendence of decline. Larger periods and greater number of cases are needed to formulate conclusions with greater significance.
[Mh] Termos MeSH primário: Agonistas de Receptores Adrenérgicos beta 2/uso terapêutico
Bloqueadores dos Canais de Cálcio/uso terapêutico
Hexoprenalina/uso terapêutico
Magnésio/uso terapêutico
Trabalho de Parto Prematuro/tratamento farmacológico
Parassimpatolíticos/uso terapêutico
Tocolíticos/uso terapêutico
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Gravidez
Tocólise/métodos
[Pt] Tipo de publicação:COMPARATIVE STUDY; ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic beta-2 Receptor Agonists); 0 (Calcium Channel Blockers); 0 (Parasympatholytics); 0 (Tocolytic Agents); G9L6B3W684 (Hexoprenaline); I38ZP9992A (Magnesium)
[Em] Mês de entrada:1501
[Cu] Atualização por classe:141216
[Lr] Data última revisão:
141216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:141217
[St] Status:MEDLINE


  2 / 139 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:25252542
[Au] Autor:Trofimov MV
[Ti] Título:[Peculiarities of treatment of ulcerative gastrointestinal hemorrhage in pregnant women].
[So] Source:Klin Khir;(6):8-10, 2014 Jun.
[Is] ISSN:0023-2130
[Cp] País de publicação:Ukraine
[La] Idioma:ukr
[Ab] Resumo:The occurrence rate of gastrointestinal hemorrhage (GIH) of nonvaricosal genesis in pregnant women was analyzed. The risk of complications occurrence in the pregnancy course while performing local endoscopic hemostasis and prophylaxis of the hemorrhage recurrence occurrence was established. Application of elaborated treatment method for GIH of nonvaricosic genesis in pregnant women have promoted reduction of the severe complications rate in the pregnancy course, applying elimination of the vasoconstrictor and uterotonic effects of adrenalin, reduction of esophagogastroduodenoscopy duration. While application of this procedure in pregnant women of a main group operative cessation of GIH was not applied. In a comparison group a hemostasis, using operative way, was done in 2 (13.3%) women patients with subsequent occurrence of preeclampsy, what resulted in antenathal fetal death.
[Mh] Termos MeSH primário: Hemorragia Gastrointestinal/epidemiologia
Hemorragia Gastrointestinal/terapia
Hemostase Endoscópica/métodos
Complicações na Gravidez/epidemiologia
Complicações na Gravidez/prevenção & controle
[Mh] Termos MeSH secundário: Dexametasona/administração & dosagem
Dexametasona/efeitos adversos
Dexametasona/uso terapêutico
Endoscopia do Sistema Digestório
Epinefrina/administração & dosagem
Epinefrina/efeitos adversos
Epinefrina/uso terapêutico
Feminino
Morte Fetal/induzido quimicamente
Morte Fetal/epidemiologia
Morte Fetal/prevenção & controle
Hemorragia Gastrointestinal/cirurgia
Hexoprenalina/administração & dosagem
Hexoprenalina/efeitos adversos
Hexoprenalina/uso terapêutico
Seres Humanos
Incidência
Soluções Isotônicas
Pré-Eclâmpsia/induzido quimicamente
Pré-Eclâmpsia/epidemiologia
Pré-Eclâmpsia/prevenção & controle
Gravidez
Complicações na Gravidez/cirurgia
Terceiro Trimestre da Gravidez
Recidiva
Estudos Retrospectivos
Cloreto de Sódio/administração & dosagem
Cloreto de Sódio/efeitos adversos
Cloreto de Sódio/uso terapêutico
Vasoconstritores/administração & dosagem
Vasoconstritores/efeitos adversos
Vasoconstritores/uso terapêutico
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Isotonic Solutions); 0 (Vasoconstrictor Agents); 451W47IQ8X (Sodium Chloride); 7S5I7G3JQL (Dexamethasone); G9L6B3W684 (Hexoprenaline); YKH834O4BH (Epinephrine)
[Em] Mês de entrada:1410
[Cu] Atualização por classe:161018
[Lr] Data última revisão:
161018
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140926
[St] Status:MEDLINE


  3 / 139 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:24500892
[Au] Autor:Neilson JP; West HM; Dowswell T
[Ad] Endereço:Department of Women's and Children's Health, The University of Liverpool, First Floor, Liverpool Women's NHS Foundation Trust, Crown Street, Liverpool, UK, L8 7SS.
[Ti] Título:Betamimetics for inhibiting preterm labour.
[So] Source:Cochrane Database Syst Rev;(2):CD004352, 2014 Feb 05.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Preterm birth is a major contributor to perinatal mortality and morbidity worldwide. Tocolytic agents are drugs used to inhibit uterine contractions. Betamimetics are tocolytic agents that have been widely used, especially in resource-poor countries. OBJECTIVES: To assess the effects of betamimetics given to women with preterm labour. SEARCH METHODS: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 December 2013) and reference lists of retrieved studies. SELECTION CRITERIA: Randomised controlled trials of betamimetics, administered by any route or any dose, in the treatment of women in preterm labour where betamimetics were compared with other betamimetics, placebo or no treatment. DATA COLLECTION AND ANALYSIS: Two review authors assessed risk of bias and extracted the data independently. MAIN RESULTS: Twenty-eight trials were assessed as eligible for inclusion in the review, but eight did not report any outcome data relevant to the review. Results are based on the 20 trials that contributed data.Twelve trials, involving 1367 women, compared betamimetics with placebo. Betamimetics decreased the number of women in preterm labour giving birth within 48 hours (average risk ratio (RR) 0.68, 95% confidence interval (CI) 0.53 to 0.88, 10 trials, 1209 women). There was a decrease in the number of births within seven days (average RR 0.80; 95% CI 0.65 to 0.98, five trials, 911 women) but there was no evidence of a reduction in preterm birth (before 37 weeks' gestation) (RR 0.95; 95% CI 0.88 to 1.03, 10 trials, 1212 women). No benefit was demonstrated for betamimetics for perinatal death (RR 0.84; 95% CI 0.46 to 1.55, 11 trials, 1332 infants), or neonatal death (RR 0.90; 95% CI 0.27 to 3.00, six trials, 1174 infants). No significant effect was demonstrated for respiratory distress syndrome (RR 0.87; 95% CI 0.71 to 1.08, eight trials, 1239 infants). A few trials reported on cerebral palsy, infant death and necrotising enterocolitis; no significant differences between groups were identified for any of these outcomes. Betamimetics were significantly associated with the following outcomes: withdrawal from treatment due to adverse effects; maternal chest pain; dyspnoea; palpitation; tremor; headaches; hypokalaemia; hyperglycaemia; nausea or vomiting; nasal stuffiness; and fetal tachycardia.Nine trials compared different types of betamimetics. Other betamimetics were compared with ritodrine in five trials (n = 948). Other comparisons were examined in single trials: hexoprenaline compared with salbutamol (n = 140), slow versus moderate release salbutamol (n = 52) and salbutamol compared with terbutaline (n = 200). Trials were small, varied, and of insufficient quality to delineate any consistent patterns of effect. AUTHORS' CONCLUSIONS: Betamimetics help to delay birth, which may give time to allow women to be transferred to tertiary care or to complete a course of antenatal corticosteroids. However, multiple adverse effects must be considered. The data are too few to support the use of any particular betamimetic.
[Mh] Termos MeSH primário: Agonistas Adrenérgicos beta/uso terapêutico
Trabalho de Parto Prematuro/prevenção & controle
Tocolíticos/uso terapêutico
[Mh] Termos MeSH secundário: Feminino
Fenoterol/uso terapêutico
Hexoprenalina/uso terapêutico
Seres Humanos
Gravidez
Nascimento Prematuro/prevenção & controle
Ensaios Clínicos Controlados Aleatórios como Assunto
Ritodrina/uso terapêutico
Terbutalina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Adrenergic beta-Agonists); 0 (Tocolytic Agents); 22M9P70OQ9 (Fenoterol); G9L6B3W684 (Hexoprenaline); I0Q6O6740J (Ritodrine); N8ONU3L3PG (Terbutaline)
[Em] Mês de entrada:1410
[Cu] Atualização por classe:160602
[Lr] Data última revisão:
160602
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140207
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD004352.pub3


  4 / 139 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24385286
[Au] Autor:Hösli I; Sperschneider C; Drack G; Zimmermann R; Surbek D; Irion O; Swiss Society of Obstetrics and Gynecology
[Ad] Endereço:Committee for Quality Assurance, Swiss Society of Obstetrics and Gynecology, Department of Obstetrics and Gynecology, University Hospital Inselspital, Effingerstrasse 102, 3010, Bern, Switzerland.
[Ti] Título:Tocolysis for preterm labor: expert opinion.
[So] Source:Arch Gynecol Obstet;289(4):903-9, 2014 Apr.
[Is] ISSN:1432-0711
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Tocolysis is an important treatment in the improvement of outcome in preterm labor and preterm birth, provided that its use follows clear evidence-based recommendations. In this expert opinion, the most recent evidence about efficacy and side effects of different tocolytics is being reviewed and evidence-based recommendation about diagnosis and treatment of preterm labor is given. Further aspects such as progesterone administration or antibiotic treatment for the prevention of preterm birth are included. Our review demonstrates that an individualized choice of different tocolytics and additional treatments is necessary to improve short- and long-term neonatal outcome in preterm labor and preterm birth.
[Mh] Termos MeSH primário: Trabalho de Parto Prematuro/tratamento farmacológico
Nascimento Prematuro/prevenção & controle
Tocólise
Tocolíticos/uso terapêutico
[Mh] Termos MeSH secundário: Antibacterianos/uso terapêutico
Repouso em Cama
Bloqueadores dos Canais de Cálcio/uso terapêutico
Medida do Comprimento Cervical
Contraindicações
Inibidores de Ciclo-Oxigenase/uso terapêutico
Aprovação de Drogas
Feminino
Fenoterol/uso terapêutico
Ruptura Prematura de Membranas Fetais
Hexoprenalina/uso terapêutico
Seres Humanos
Recém-Nascido
Kalanchoe
Primeira Fase do Trabalho de Parto
Sulfato de Magnésio/uso terapêutico
Doadores de Óxido Nítrico/uso terapêutico
Fitoterapia
Gravidez
Progesterona/uso terapêutico
Progestinas/uso terapêutico
Receptores de Ocitocina/antagonistas & inibidores
Ultrassonografia Pré-Natal
[Pt] Tipo de publicação:JOURNAL ARTICLE; PRACTICE GUIDELINE; REVIEW
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Calcium Channel Blockers); 0 (Cyclooxygenase Inhibitors); 0 (Nitric Oxide Donors); 0 (Progestins); 0 (Receptors, Oxytocin); 0 (Tocolytic Agents); 22M9P70OQ9 (Fenoterol); 4G7DS2Q64Y (Progesterone); 7487-88-9 (Magnesium Sulfate); G9L6B3W684 (Hexoprenaline)
[Em] Mês de entrada:1410
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140104
[St] Status:MEDLINE
[do] DOI:10.1007/s00404-013-3137-9


  5 / 139 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:22611112
[Au] Autor:Mayer M; Minichmayr A; Klement F; Hroncek K; Wertaschnigg D; Arzt W; Wiesinger-Eidenberger G; Lechner E
[Ad] Endereço:Department of Neonatology, Children's and Maternity Hospital Linz, Linz 4020, Austria. michael.mayer@gespag.at
[Ti] Título:Tocolysis with the ß-2-sympathomimetic hexoprenaline increases occurrence of infantile haemangioma in preterm infants.
[So] Source:Arch Dis Child Fetal Neonatal Ed;98(2):F108-11, 2013 Mar.
[Is] ISSN:1468-2052
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Infantile haemangioma (IH) is the most commonly observed tumour in children. Off-label pharmacological treatment of IH with the beta-blocker propranolol induces regression of IH. Based on the fact that IH are more frequently observed in premature babies than in mature babies and the evidence that beta-blocker therapy leads to regression of IH, the authors generated the hypothesis that the use of ß-2-sympathomimetics during pregnancy for inhibiting premature labour might increase occurrence of IH in preterm infants. METHODS: For group comparison t test, Mann-Whitney U test and Fisher's exact test were used. Logistic regression was carried out by the forward stepwise method with Wald statistics. RESULTS: Data of 328 preterm infants (<32 gestational weeks) or with a birth weight of less than 1500 g (<36 gestational weeks) born between January 2006 and December 2008 were analysed. A total of 15 were excluded due do death within the 1st month of life, 38 because of lost to follow-up and six due to incomplete data. Complete data of 269 preterm infants were retrospectively analysed. During the follow-up period of median 1.6 years, 50 infants developed one or more IH within their first 6 months of life. IH occurred in 40/181 patients with intrauterine exposure to the ß-2-sympathomimetic hexoprenaline and in 10/88 without exposure (OR=4.3; 95% CI 1.4 to 13.8). Furthermore, the influence of antenatal exposure to glucocorticosteroids for induction of lung development was analysed. Prenatally exposed subjects showed reduced occurrence of IH (OR=0.2; 95% CI 0.05 to 0.8). CONCLUSION: Intrauterine exposure to the ß-2-sympathomimetic hexoprenaline might increase the occurrence of IH in preterm infants.
[Mh] Termos MeSH primário: Agonistas de Receptores Adrenérgicos beta 2/efeitos adversos
Hemangioma/induzido quimicamente
Hexoprenalina/efeitos adversos
Doenças do Prematuro/induzido quimicamente
Tocolíticos/efeitos adversos
[Mh] Termos MeSH secundário: Agonistas de Receptores Adrenérgicos beta 2/uso terapêutico
Feminino
Glucocorticoides/uso terapêutico
Hemangioma/prevenção & controle
Hexoprenalina/uso terapêutico
Seres Humanos
Recém-Nascido
Recém-Nascido Prematuro
Doenças do Prematuro/prevenção & controle
Masculino
Troca Materno-Fetal
Trabalho de Parto Prematuro/prevenção & controle
Gravidez
Efeitos Tardios da Exposição Pré-Natal/induzido quimicamente
Estudos Retrospectivos
Tocólise/efeitos adversos
Tocolíticos/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic beta-2 Receptor Agonists); 0 (Glucocorticoids); 0 (Tocolytic Agents); G9L6B3W684 (Hexoprenaline)
[Em] Mês de entrada:1305
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:120522
[St] Status:MEDLINE
[do] DOI:10.1136/archdischild-2011-301030


  6 / 139 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:23097963
[Au] Autor:Islami H; Veseli A; Behluli E; Morina N
[Ad] Endereço:Department of Pharmacology, Faculty of Medicine, University of Prishtina. Clinical Centre, Prishtina, Kosova. islamihilmi@hotmail.com
[Ti] Título:Importance of the adrenergic nerve system in the response of gases in the arterial blood following the provoked bronchospasm.
[So] Source:Med Arch;66(5):292-5, 2012.
[Is] ISSN:0350-199X
[Cp] País de publicação:Bosnia and Herzegovina
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: This work, partial pressure of the respiratory gases in the capillary blood (pH, PaO2, PaCO2) was studied, following the protective action of the beta2-drenergic stimulator-Hexoprenaline and alpha2-adrenergic blocker-Tolazoline in the bronchoconstriction caused by a beta-blocker-Propranolol. MATERIAL AND METHODS: in patients with increased bronchial reactibility. pH, oxygen partial pressure (PaO2), dioxide carbon partial pressure (PaCO2) in the arterial blood, with the assistance of the analyzer IL, following some minutes of sample taking were defined in all patients. As a standard to verify the accuracy of the measurement, ampoule solutions of pH, PaO2 and PaCO2 were utilized (Acidobasel, Berlin). RESULTS AND DISCUSSION: Following the inhalation of the beta-blocker-Propranolol (20 mg/ml-aerosol), there was an evident decrease (p < 0.05) of pO2 and a non-significant increase (p > 0.1) of pCO2. Beta2-adrenergcic stimulator-Hexoprenaline (2 inh x 0.2 mg), shows an protective effect in the decrease of pO2 (p < 0.05) following the bronchoconstriction being provoked by Propranolol. Alpha2-adrenergic blocker-Tolazoline (20 mg/ml-aerosol), has not shown a protective action in the bronchoconstriction caused with propranolol, therefore significant decrease (p < 0.05) of pO2 and a non-significant increase (p > 0.1) of pCO2 appeared. This shows that stimulation of beta2-adrenergic receptor has protective action in changes of the respiratory gases. Meantime, blocker of the alpha2-adrenergic receptor (Tolazoline) has not shown a protective action in changes of the respiratory gases.
[Mh] Termos MeSH primário: Espasmo Brônquico/fisiopatologia
Dióxido de Carbono/sangue
Oxigênio/sangue
Receptores Adrenérgicos/fisiologia
[Mh] Termos MeSH secundário: Antagonistas Adrenérgicos alfa/farmacologia
Agonistas de Receptores Adrenérgicos beta 2
Antagonistas Adrenérgicos beta/farmacologia
Adulto
Feminino
Hexoprenalina/farmacologia
Seres Humanos
Masculino
Pressão Parcial
Propranolol/farmacologia
Doença Pulmonar Obstrutiva Crônica/fisiopatologia
Troca Gasosa Pulmonar
Tolazolina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic alpha-Antagonists); 0 (Adrenergic beta-2 Receptor Agonists); 0 (Adrenergic beta-Antagonists); 0 (Receptors, Adrenergic); 142M471B3J (Carbon Dioxide); 9Y8NXQ24VQ (Propranolol); CHH9H12AQ3 (Tolazoline); G9L6B3W684 (Hexoprenaline); S88TT14065 (Oxygen)
[Em] Mês de entrada:1212
[Cu] Atualização por classe:150901
[Lr] Data última revisão:
150901
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:121027
[St] Status:MEDLINE


  7 / 139 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:20963649
[Au] Autor:Chereshnev VA; Shilov JI; Chereshneva MV; Chuprina VV; Gavrilova TV
[Ad] Endereço:Institute of Immunology and Physiology, Russian Academy of Sciences, ul. Pervomaiskaya 91, Yekaterinburg, 620041, Russia.
[Ti] Título:Dependence of the lymphocyte proliferative response on the endogenous cortisol level and sensitivity to ß-adrenergic regulation in vitro in the early period of penetrating eye injury.
[So] Source:Dokl Biol Sci;434:304-6, 2010 Sep-Oct.
[Is] ISSN:0012-4966
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Agonistas de Receptores Adrenérgicos beta 2/farmacologia
Ferimentos Oculares Penetrantes/imunologia
Hexoprenalina/farmacologia
Hidrocortisona/sangue
Ativação Linfocitária/efeitos dos fármacos
[Mh] Termos MeSH secundário: Adulto
Proliferação Celular/efeitos dos fármacos
Seres Humanos
Masculino
Meia-Idade
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Adrenergic beta-2 Receptor Agonists); G9L6B3W684 (Hexoprenaline); WI4X0X7BPJ (Hydrocortisone)
[Em] Mês de entrada:1101
[Cu] Atualização por classe:171019
[Lr] Data última revisão:
171019
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:101022
[St] Status:MEDLINE
[do] DOI:10.1134/S0012496610050030


  8 / 139 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:16338281
[Au] Autor:Landau R; Morales MA; Antonarakis SE; Blouin JL; Smiley RM
[Ad] Endereço:Division of Anesthesiology and Department of Obstetrics and Gynecology, University Hospital of Geneva, University of Geneva Medical School, Geneva, Switzerland. ruth.landau@hcuge.ch
[Ti] Título:Arg16 homozygosity of the beta2-adrenergic receptor improves the outcome after beta2-agonist tocolysis for preterm labor.
[So] Source:Clin Pharmacol Ther;78(6):656-63, 2005 Dec.
[Is] ISSN:0009-9236
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Beta(2)-adrenergic receptor (beta(2)AR) agonists are not consistently successful when administered as tocolytic therapy. The beta(2)AR displays genetic variability; an arginine-to-glycine substitution at codon 16 (Arg16Gly) has been shown to increase receptor desensitization in response to agonist exposure, whereas a substitution of glutamate for glutamine at codon 27 (Gln27Glu) decreases down-regulation. We have demonstrated that homozygosity for Arg16 protects against preterm delivery. Our goal was to determine whether beta(2)-agonists are more effective in women with the Arg16 genotype and preterm labor. METHODS: Sixty white women with preterm labor between 24 and 34 weeks' gestation were treated for 48 hours with intravenous hexoprenaline. The effect of tocolysis and outcome of pregnancy were recorded. The beta(2)AR genotypes at codons 16 and 27 of ADRB2 were determined. A control group of 116 women delivered at term was also genotyped. RESULTS: Preterm labor was not associated with beta(2)AR genotype at codon 16 (17% of patients with preterm labor were Arg16 homozygotes versus 19% of control subjects) or codon 27. Gestation was significantly prolonged in Arg16 homozygotes (median, 69 days; interquartile range, 63-79 days) compared with the other 2 genotypes (median, 58 days; interquartile range, 2-72 days) (P = .04). Tocolysis was 100% successful in delaying delivery for 48 hours in Arg16 homozygotes (n = 10), just failing to achieve statistical significance (P = .069). In contrast, only 37 of 50 women carrying 1 or 2 glycine alleles (74%) had delivery delayed by more than 48 hours with tocolysis. Neonatal outcomes were significantly better in babies born to mothers homozygous for arginine than in women with 1 or 2 Gly16 alleles. CONCLUSIONS: This is the first study examining the pharmacogenetics of beta(2)AR agonist therapy for preterm labor. It appears that Arg16 homozygosity improves pregnancy outcome after beta(2)-agonist tocolysis. The relatively low frequency of Arg16 homozygotes in our population limited the power of this investigation. Future assessments of tocolytic therapy may need to assess beta(2)AR genotype.
[Mh] Termos MeSH primário: Arginina/genética
Hexoprenalina/uso terapêutico
Trabalho de Parto Prematuro/prevenção & controle
Receptores Adrenérgicos beta 2/genética
[Mh] Termos MeSH secundário: Agonistas de Receptores Adrenérgicos beta 2
Agonistas Adrenérgicos beta/administração & dosagem
Agonistas Adrenérgicos beta/uso terapêutico
Adulto
Alelos
Substituição de Aminoácidos/genética
Feminino
Frequência do Gene
Glicina/genética
Haplótipos
Hexoprenalina/administração & dosagem
Homozigoto
Seres Humanos
Recém-Nascido de Baixo Peso
Recém-Nascido
Trabalho de Parto Prematuro/genética
Gravidez
Resultado da Gravidez
Síndrome do Desconforto Respiratório do Recém-Nascido/genética
Taquicardia/genética
Tocólise/métodos
Tocolíticos/administração & dosagem
Tocolíticos/uso terapêutico
[Pt] Tipo de publicação:CLINICAL TRIAL; COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Adrenergic beta-2 Receptor Agonists); 0 (Adrenergic beta-Agonists); 0 (Receptors, Adrenergic, beta-2); 0 (Tocolytic Agents); 94ZLA3W45F (Arginine); G9L6B3W684 (Hexoprenaline); TE7660XO1C (Glycine)
[Em] Mês de entrada:0604
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:051213
[St] Status:MEDLINE


  9 / 139 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:15738517
[Au] Autor:Zhong XY; Holzgreve W; Hoesli I; Hahn S
[Ad] Endereço:Laboratory for Prenatal Medicine, University Women's Hospital, Department of Research, University Hospital Basel, Basel, Switzerland.
[Ti] Título:Circulatory corticotropin-releasing hormone mRNA concentrations are increased in women with preterm delivery but not in those who respond to tocolytic treatment.
[So] Source:Clin Chem;51(3):635-6, 2005 Mar.
[Is] ISSN:0009-9147
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Hormônio Liberador da Corticotropina/sangue
Hexoprenalina/uso terapêutico
Trabalho de Parto Prematuro/sangue
RNA Mensageiro/sangue
Tocolíticos/uso terapêutico
[Mh] Termos MeSH secundário: Hormônio Liberador da Corticotropina/genética
Feminino
Feto
Idade Gestacional
Seres Humanos
Trabalho de Parto Prematuro/prevenção & controle
Gravidez
Estudos Retrospectivos
Reação em Cadeia da Polimerase Via Transcriptase Reversa
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (RNA, Messenger); 0 (Tocolytic Agents); 9015-71-8 (Corticotropin-Releasing Hormone); G9L6B3W684 (Hexoprenaline)
[Em] Mês de entrada:0504
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:050302
[St] Status:MEDLINE


  10 / 139 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:15495104
[Au] Autor:Anotayanonth S; Subhedar NV; Garner P; Neilson JP; Harigopal S
[Ad] Endereço:Chonburi Hospital, Ampur Muang, Chonburi, Thailand, 20000. dr_suchada@hotmail.com
[Ti] Título:Betamimetics for inhibiting preterm labour.
[So] Source:Cochrane Database Syst Rev;(4):CD004352, 2004 Oct 18.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Preterm birth is a major contributor to perinatal mortality and morbidity worldwide. Tocolytic agents are drugs used to inhibit uterine contractions. The most widely used tocolytic agents are betamimetics especially in resource-poor countries. OBJECTIVES: To assess the effects of betamimetics given to women with preterm labour. SEARCH STRATEGY: We searched the Cochrane Pregnancy and Childbirth Group trials register (May 2003) without language restrictions. SELECTION CRITERIA: Randomised controlled trials of betamimetics, administered by any route or any dose, in the treatment of women in preterm labour where betamimetics are compared with other betamimetics, placebo or no treatment. DATA COLLECTION AND ANALYSIS: Two reviewers evaluated independently methodological quality and extracted the data. We sought additional information to enable assessment of methodology and conduct intention-to-treat analyses. We present the results using the relative risk for categorical data and the weighted mean difference for continuous data. MAIN RESULTS: Eleven randomised controlled trials, involving 1332 women, compared betamimetics with placebo. Betamimetics decreased the number of women in preterm labour giving birth within 48 hours (relative risk (RR) 0.63; 95% confidence interval (CI) 0.53 to 0.75) but there was no decrease in the number of births within seven days after carrying out a sensitivity analysis of studies with adequate allocation of concealment. No benefit was demonstrated for betamimetics on perinatal death (RR 0.84; 95% CI 0.46 to 1.55, 7 trials, n = 1332), or neonatal death (RR 1.00; 95% CI 0.48 to 2.09, 5 trials, n = 1174). No significant effect was demonstrated for respiratory distress syndrome (RR 0.87; 95% CI 0.71 to 1.08, 8 trials, n = 1239). A few trials reported the following outcomes, with no difference detected: cerebral palsy, infant death and necrotizing enterocolitis. Betamimetics were significantly associated with the following: withdrawal from treatment due to adverse effects; chest pain; dyspnoea; tachycardia; palpitation; tremor; headaches; hypokalemia; hyperglycemia; nausea/vomiting; and nasal stuffiness; and fetal tachycardia. Other betamimetics were compared with ritodrine in five trials (n = 948). Trials were small, varied and of insufficient quality to delineate any consistent patterns of effect. REVIEWERS' CONCLUSIONS: Betamimetics help to delay delivery for women transferred to tertiary care or completed a course of antenatal corticosteroids. However, multiple adverse effects must be considered. The data are too few to support the use of any particular betamimetics.
[Mh] Termos MeSH primário: Agonistas Adrenérgicos beta/uso terapêutico
Trabalho de Parto Prematuro/prevenção & controle
Tocolíticos/uso terapêutico
[Mh] Termos MeSH secundário: Feminino
Fenoterol/uso terapêutico
Hexoprenalina/uso terapêutico
Seres Humanos
Gravidez
Ensaios Clínicos Controlados Aleatórios como Assunto
Ritodrina/uso terapêutico
Terbutalina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Adrenergic beta-Agonists); 0 (Tocolytic Agents); 22M9P70OQ9 (Fenoterol); G9L6B3W684 (Hexoprenaline); I0Q6O6740J (Ritodrine); N8ONU3L3PG (Terbutaline)
[Em] Mês de entrada:0503
[Cu] Atualização por classe:140326
[Lr] Data última revisão:
140326
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:041021
[St] Status:MEDLINE



página 1 de 14 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde